Introduction {#Sec1}
============

Diabetic macular edema (DME) currently affects approximately 20 million people worldwide \[[@CR1]\]. At the present time intravitreal anti-vascular endothelial growth factor (VEGF) therapy is the standard of care \[[@CR1]--[@CR6]\]. A network meta-analysis that included 24 clinical studies with 6007 participants confirmed that anti-VEGF therapy offers greater improvement in visual acuity (VA) than does laser photocoagulation, with an acceptable safety profile \[[@CR4]\]. These improvements usually occur within 1 year and can be sustained for up to 5 years \[[@CR2], [@CR3], [@CR7]\].

For the treatment of visual impairment due to DME, German medical societies \[[@CR8]\] recommend an initial upload of four anti-VEGF injections at monthly intervals, followed by two injections monthly and then by a single monthly injection if further treatment is needed. Monthly assessments of retinal thickness by optical coherence tomography (OCT) and VA should guide re-treatment (Electronic Supplementary Material \[ESM\] Fig. S1). These societies also recommend performing fluorescein angiography (FA) and OCT before initiating anti-VEGF therapy to confirm DME as the treatment indication and to detect ischemic maculopathy or permanent damage to the retina, both of which predict poor response to treatment \[[@CR8]\].

In the clinical trials reported to date, an average of 7--12 injections were administered in the first year and three to six injections in the second year \[[@CR2], [@CR3], [@CR9], [@CR10]\]. Adhering to this schedule can be difficult outside of clinical trials, which may lead to under-treatment \[[@CR4]\]. Moreover, older patients and a higher frequency of comorbidities in a real-world setting may further reduce adherence to monitoring and therapy and impair the effectiveness of ranibizumab for the management of DME \[[@CR11], [@CR12]\]. The effects of these factors merit evaluation, but such evaluations have so far been largely undocumented or restricted to retrospective data \[[@CR13]--[@CR15]\].

Therefore, we have prospectively examined the effectiveness, treatment, monitoring and safety of ranibizumab (0.5 mg) injections in individuals with DME in Germany in the real-world, non-interventional OCEAN (Observation of treatment patterns with LuCEntis and real-life ophthalmic monitoring, including optional OCT in Approved iNdications) study.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

The prospective, multicenter, non-interventional OCEAN study examined the use of intravitreal ranibizumab in adults with neovascular, exudative or edematous eye diseases, under real-world conditions in Germany \[[@CR11]\]. One eye per patient was included. The OCEAN study was approved by the ethics committee of the Eberhard-Karls-University, Tübingen, Germany. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Here we describe the subpopulation treated with ranibizumab for visual impairment due to DME, accounting for 21.6% of the OCEAN safety population (1250 of 5781 participants). Data were collected between December 2011 and December 2016.

Participants and Study Centers {#Sec4}
------------------------------

The aims of the OCEAN study \[[@CR11]\] were to provide a representative picture of ophthalmologists in Germany and of the individuals treated with ranibizumab. Exclusion criteria were contra-indications based on the Summary of Product Characteristics, intravitreal anti-VEGF treatment of the study eye in the 3 months prior to enrolment or previous intravitreal steroid treatment. The subpopulation described here included only patients with diabetes mellitus and center-involved DME as the primary indication for ranibizumab. Participants with DME were recruited by 250 of the 369 OCEAN study centers, among which were 49 general ophthalmology practices (of the 4735 such practices in Germany) and 201 retina specialist centers (of the approximately 1200 such centers in Germany).

Evaluation {#Sec5}
----------

Data were collected prospectively by the treating physicians. Demographics, clinical characteristics, previous ranibizumab injections, VA and results from OCT and FA were recorded at baseline. At subsequent visits, the date, whether an injection was administered or not (plus reason for decision), VA and OCT measurements and any adverse events (AEs) were captured along with premature discontinuation of treatment or documentation.

Values for best-corrected VA were converted to logarithm of minimum angle of resolution (LogMAR) values and Early Treatment Diabetic Retinopathy Study (ETDRS) letters \[[@CR16]\].

AEs were reported according to World Health Organization guidelines \[[@CR17]\].

Data Analysis {#Sec6}
-------------

The safety population includes all enrolled participants receiving ≥ 1 ranibizumab injection within OCEAN with at least one safety assessment. The full analysis set (FAS) includes all eligible participants. The potential influence of baseline VA was delineated by defining three subpopulations based on approximate tertiles of baseline VA (\< 55 ETDRS letters, 55--68 letters, \> 68 letters). Further subgroup analyses were conducted stratified by sex, pre-treatment status (treatment-naïve: no documented previous intravitreal anti-VEGF treatment and ≤ 90 days between diagnosis and first injection within OCEAN; pre-treated: received anti-VEGF treatment \> 3 months before study entry; remaining participants were considered to be possibly pre-treated) and number of injections in the first year.

Data analysis was performed using SAS^®^ software, version 9.4 (SAS Institute Inc., Cary, NC, USA). Data are presented descriptively as the mean with the 95% confidence interval (95% CI), the mean with the standard deviation or the percentage of patients. To account for missing data inherent to the non-interventional design of the study \[[@CR11], [@CR18]\], time-to-discontinuation, time-to-response (to first improvement of ≥ 15 ETDRS letters from baseline) and duration-of-response (time from first improvement of ≥ 15 ETDRS letters to first time point of losing this improvement) were analyzed using Kaplan--Meier estimates.

Results {#Sec7}
=======

Study Population {#Sec8}
----------------

After verifying eligibility in 1250 participants (safety population), data from 1226 participants (774 treatment-naïve, 181 pre-treated, 301 possibly pre-treated) were included in the effectiveness analysis (FAS) (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flow chart of disposition of patients with diabetic macular edema (DME) in the OCEAN study. Asterisk refers to reasons for exclusion from the full analysis set: pre-treatment of study eye with intravitreal anti-vascular endothelial growth factor (VEGF) within the last 3 months and/or pre-treatment with intravitreal steroids in the past (*n* = 12); not documented that DME was present and that ranibizumab treatment was medically indicated and planned (*n* = 7); pre-treatment with ranibizumab within the last 3 months (*n* = 4); and major, unresolvable errors in the visit chronology (*n* = 1). Dagger denotes multiple responses possible. Double dagger denotes that documentation discontinued before month 24. Double S denotes 'Other reason' for premature discontinuation of documentation and was most frequently specified as change to 'other anti-VEGF medication' (*n* = 49), change to aflibercept (*n* = 25) or change to bevacizumab (*n* = 19). Hashtag denotes the 947 participants with a documented visit at month 12 and the 30 participants who did not have a visit at month 12 but did have a later documented visit. Degree symbol denotes participants with a documented visit at month 24

The mean baseline age was 67.6 years, 57.5% of the population were men and 77.4% had type 2 diabetes mellitus (Table [1](#Tab1){ref-type="table"}).Table 1Baseline characteristics of study participants with diabetic macular edema (full analysis set, *n  *= 1226)ParameterValues^a^Age (years)^b^67.6 ± 10.8Gender Men705 (57.5%) Women515 (42.0%) Missing6 (0.5%)Anamnestic risk factors^c^ Diabetes mellitus1226 (100.0%)  Type I118 (9.6%)  Type II949 (77.4%)  Unknown90 (7.3%)  Missing70 (5.7%) Hypercholesterolemia184 (15.0%) Neovascular disease of the other eye176 (14.4%) Hyperlipidemia92 (7.5%) Myocardial infarction84 (6.9%) Family history of coronary artery disease69 (5.6%) Apoplexy66 (5.4%) Other thromboembolism event31 (2.5%) Other metabolic dysfunction22 (1.8%) Other risk factors339 (27.7%)HbA1c (mmol/mol)^b^58 ± 13HbA1c (%)^b^7.5 ± 1.2HbA1c (categories) \< 64 mmol/mol (\< 8.0%)504 (41.1%) ≥ 64 mmol/mol (≥ 8.0%)220 (17.9%) Missing502 (41.0%)OCT examination at baseline Performed943 (76.9%) Not performed276 (22.5%) Missing7 (0.6%)FA examination at baseline Performed852 (69.5%) Not performed367 (29.9%) Missing7 (0.6%)OCT and FA examination at baseline OCT = yes, FA = yes654 (53.3%) OCT = yes, FA = no289 (23.6%) OCT = no, FA = yes198 (16.2%) OCT = no, FA = no77 (6.3%) Missing8 (0.7%)*FA* Fluorescein angiography, *HbA1c* glycated hemoglobin A1c, *OCT* optical coherence tomography^a^Values are presented as the mean ± standard deviation (SD) or as a number with the percentage in parenthesis, as appropriate^b^Data for some participants are missing: age (9 missing), HbA1c (502 missing)^c^Multiple responses possible

Follow-up, Treatment and Monitoring {#Sec9}
-----------------------------------

Of the 1226 participants in the FAS, 977 (79.7%) completed the first 12 months of the study and 738 (60.2%) completed 24 months (Fig. [1](#Fig1){ref-type="fig"}). Premature study discontinuation was documented for 391 participants (31.9%), mainly due to loss to follow-up (134 participants) or "other reasons" (194 participants).

The mean observational period was 507.1 (95% CI 492.8; 521.3) days.

The study participants received on average 4.42 (95% CI 4.30; 4.54) ranibizumab injections in the first year and 5.52 (95% CI 5.32; 5.73) injections over 24 months (Fig. [2](#Fig2){ref-type="fig"}). The number of injections did not differ by baseline VA (Table [2](#Tab2){ref-type="table"}).Fig. 2Mean number of injections administered during the first 12 months and during the entire 24-month observational period of the OCEAN study compared to current German recommendations. Error bars depict confidence intervals. Asterisk denotes the expected number of injections is based on an initial upload of four injections at monthly intervals, followed by two additional monthly injections as needed and then by single monthly injections as needed, as recommended by German medical societies. According to these recommendations it is expected that on average seven to eight injections are given during the first year and fewer than four injections are given in the second year \[[@CR2], [@CR8], [@CR30]\] Table 2Treatment with ranibizumab for diabetic macular edema and monitoring by optical coherence tomography in the OCEAN study (full analysis set, *n  *= 1226)ParameterAll participantsTreatment-naïvePre-treated*n*Values^a^*n*Values^a^*n*Values^a^All participants, including those who discontinued prematurely Number of injections in the first year (to month 12), by baseline VA^b^ in ETDRS letters  \< 55 Letters3714.52 \[4.29; 4.74\]2174.61 \[4.30; 4.91\]534.87 \[4.19; 5.55\]  55--68 Letters3824.26 \[4.05; 4.47\]2414.33 \[4.06; 4.60\]554.24 \[3.62; 4.85\]  \> 68 Letters4644.50 \[4.29; 4.71\]3094.56 \[4.31; 4.82\]724.79 \[4.21; 5.37\] Number of injections over the observational period (to month 24), by baseline VA^b^ in ETDRS letters  \< 55 Letters3715.62 \[5.25; 5.99\]2175.72 \[5.22; 6.21\]536.32 \[5.15; 7.49\]  55--68 Letters3825.34 \[4.99; 5.69\]2415.30 \[4.86; 5.73\]556.05 \[4.98; 7.13\]  \> 68 Letters4645.64 \[5.30; 5.99\]3094.64 \[5.25; 6.04\]726.38 \[5.26; 7.49\] Participants receiving a four-injection upload^c^  Total1226 (100.0%)774 (100.00%)181 (100.0%)  Yes410 (33.4%)270 (34.9%)46 (25.4%)  No816 (66.6%)504 (65.1%)135 (74.6%) Number of OCT examinations  To month 1212263.7 \[3.5; 3.9\]7743.7 \[3.5; 3.9\]1814.0 \[3.6; 4.4\]  To month 2412265.9 \[5.6; 6.2\]7745.9 \[5.5; 6.4\]1816.5 \[5.7; 7.3\]Only participants completing the 24 months observational period Number of injections in the first year (to month 12), by baseline VA^b^ in ETDRS letters  \< 55 Letters2104.92 \[4.61; 5.23\]1205.05 \[4.63; 5.47\]365.22 \[4.36; 6.09\]  55--68 Letters2394.62 \[4.35; 4.89\]1484.77 \[4.43; 5.11\]344.68 \[3.87; 5.48\]  \> 68 Letters2884.80 \[4.52; 5.07\]1864.88 \[4.54; 5.21\]455.29 \[4.51; 6.06\] Number of injections over the observational period (to month 24), by baseline VA^b^ in ETDRS letters  \< 55 Letters2106.61 \[6.06; 7.16\]1206.72 \[5.99; 7.45\]367.31 \[5.75; 8.87\]  55--68 Letters2396.16 \[5.68; 6.65\]1486.15 \[5.55; 6.74\]347.32 \[5.86; 8.79\]  \> 68 Letters2886.48 \[6.00; 6.96\]1866.50 \[5.95; 7.05\]457.64 \[6.07; 9.21\]Participants receiving a four-injection upload^c^  Total738 (100.0%)455 (100.0%)115 (100.0%)  Yes241 (32.7%)155 (34.1%)31 (27.0%)  No497 (67.3%)300 (65.9%)84 (73.0%)Number of OCT examinations  To month 127384.1 \[3.8; 4.3\]4454.2 \[3.8; 4.5\]1154.6 \[4.0; 5.2\]  To month 247387.5 \[7.0; 7.9\]4457.6 \[6.9; 8.2\]1158.4 \[7.3; 9.4\]*CI* confidence interval, *ETDRS* Early Treatment Diabetic Retinopathy Study,*VA* visual acuity^a^Values are presented as the mean with the 95% confidence interval (CI) in square brackets or as a number with the percentage in parenthesis, as appropriate^b^VA was assessed as best-corrected VA^c^Counted are patients with three injections after the baseline injection, with not more than 37 days between each injection in this series and the previous one

The longest interval was documented between the third and the fourth injection (Fig. [3](#Fig3){ref-type="fig"}). A four-injection upload was documented in 33.4% of the participants (Table [2](#Tab2){ref-type="table"}).Fig. 3Time intervals between the first five injections during the OCEAN study and the respective next injection. Number of patients are plotted against the respective category of time intervals (days)

Baseline OCT and FA examinations were reported for 77 and 70% of the participants, respectively (Table [1](#Tab1){ref-type="table"}).

Over 12 and 24 months, a mean of 3.7 and 5.9 OCT examinations were performed in the FAS (Table [2](#Tab2){ref-type="table"}). During the first year, 879 participants (71.7%) had ≥ 2 documented OCT examinations, 192 (15.7%) had one OCT examination and 155 (12.6%) did not have a OCT examination.

All participants received a mean of 8.6 (95% CI 8.5; 8.8) and 14.2 (95% CI 13.8; 14.7) VA examinations over 12 and 24 months, respectively. For the 738 participants completing 24 months of the study, 9.8 (95% CI 9.6; 10.0) and 18.3 (95% CI 17.8; 18.7) VA examinations were documented, respectively.

Visual Acuity {#Sec10}
-------------

The mean baseline VA was 60.6 (95% CI 59.7; 61.5) ETDRS letters, with 464, 382 and 371 participants in the VA sub-groups of \> 68 ETDRS letters, 55--68 letters and \< 55 letters, respectively.

In the FAS, the mean VA was above baseline throughout the observation period (Table [3](#Tab3){ref-type="table"}; ESM Table S1). VA improvement peaked initially at month 3 (+ 4.9 \[95% CI 4.1\] 5.6 ETDRS letters), then remained relatively stable until month 12 (+ 4.0 ETDRS letters) and increased at the end of year 2, reaching + 5.2 ETDRS letters at month 24 (Fig. [4](#Fig4){ref-type="fig"}a; Table [3](#Tab3){ref-type="table"}). In general, the discontinuation rate was constant (Fig. [4](#Fig4){ref-type="fig"}b).Table 3Visual acuity of participants with diabetic macular edema in the OCEAN study, at baseline and at months 12 and 24 of the observational period (full analysis set, *n  *= 1226)ParameterAll participantsTreatment-naïvePre-treated*n*Values^a^*n*Values^a^*n*Values^a^Visual acuity^b^, ETDRS letters Baseline121760.6 \[59.7; 61.5\]76761.5 \[60.4; 62.5\]18061.2 \[59.0; 63.3\] Month 1264265.0 \[63.5; 66.5\]41865.6 \[63.8; 67.5\]8764.8 \[60.7; 68.8\] Month 2437165.5 \[63.5; 67.4\]23866.4 \[64.1; 68.6\]4967.0 \[61.9; 72.2\] Δ Mo 12--BL638+ 4.0 \[2.9; 5.2\]414+ 4.1 \[2.7; 5.6\]87+ 3.6 \[0.0; 7.1\] Δ Mo 24--BL370+ 5.2 \[3.7; 6.7\]237+ 5.4 \[3.7; 7.0\]49+ 6.3 \[2.8; 9.9\]Participants with documented response at month 24 in ETDRS letters Total638 (100.0%)414 (100.0%)87 (100.0%) ≥ 15 Letter gain137 (21.5%)89 (21.5%)18 (20.7%) Change between  ≥ 15 and \< 15  letters455 (71.3%)297 (71.7%)61 (70.1%)≥ 15 letter loss46 (7.2%)28 (6.8%)8 (9.2%)Participants with documented response at month 24 in ETDRS letters Total370 (100.0%)237 (100.0%)49 (100.0%) ≥ 15 Letter gain87 (23.5%)48 (20.3%)16 (32.7%)Change between  ≥ 15 and \< 15 letters257 (69.5%)176 (74.3%)29 (59.2%) ≥ 15 Letter loss26 (7.0%)13 (5.5%)4 (8.16%)*BL* Baseline,*Mo* month^a^Values are presented as the mean with the 95% CI in square brackets or as a number with the percentage in parenthesis, as appropriate^b^Visual acuity was assessed as best-corrected VA Fig. 4Mean change of best-corrected visual acuity (*VA*) from baseline in participants with DME by pre-treatment status (**a**), and the corresponding total number of patients who discontinued the study (**b**) during the 24-month observational period. *ETDRS* Early Treatment Diabetic Retinopathy Study, Boxes in **a** represent mean changes and error bars represent 95% confidence intervals (CI). Gray bars represent number of patients

At months 12 and 24, \> 20% of the participants gained ≥ 15 ETDRS letters versus baseline, whereas VA deteriorated by ≥ 15  letters in about 7% of participants (Table [3](#Tab3){ref-type="table"}). The VA improvement was highest in participants with the lowest baseline VA and lowest in those with the highest baseline VA (ESM Fig. S2a). Baseline VA and changes from baseline (ESM Table S2, ESM Fig. S2b) were similar for participants given one to three or four to six ranibizumab injections, with a slightly greater improvement in those receiving ≥ 7 injections. The number of injections was similar in the  subgroups  according to baseline VA (Table [2](#Tab2){ref-type="table"}). Overall, VA improvements were comparable between pre-treated and treatment-naïve participants in the first year, but slightly better in the pre-treated group towards the end of the study (Fig. [4](#Fig4){ref-type="fig"}a). At 24 months, 32.7% of the pre-treated but only 20.3% of the treatment-naïve participants had gained ≥ 15 ETDRS letters.

Time-to-Event Analyses {#Sec11}
----------------------

The rate of premature study discontinuation was relatively constant throughout the study (Fig. [5](#Fig5){ref-type="fig"}a). The probability of a participant remaining in the study up to month 12 and month 24 was approximately 75 and 60%, respectively. The rate and time course of discontinuations did not differ by pre-treatment status (Fig. [5](#Fig5){ref-type="fig"}b), sex and baseline VA (ESM Fig. S3a, b). A higher proportion of participants receiving one to three injections during the first 12 months were documented for a shorter period of time compared to those receiving more injections (ESM Fig. S3c).Fig. 5Time-to-discontinuation in all patients (full analysis set \[FAS\] *n* = 1226) (**a**) and by pre-treatment status (**b**). If the time of discontinuation was not documented, it was set to day 1. Estimators are based on the Kaplan--Meier (*KM*) product-limit methodology.*BL* Baseline, *mo* Months. The dashed line represents the 1 year time point

Time-to-response and duration-of-response were analyzed by pre-treatment status and number of documented ranibizumab injections in the first year.

About 20% of treatment-naïve participants had a ≥ 15 ETDRS letter response within the first 3 months in all injection subgroups. Thereafter, the response rate was higher in participants receiving ≥ 7 injections than  in those receiving fewer injections (Fig. [6](#Fig6){ref-type="fig"}a). In participants who showed a ≥ 15  ETDRS letter response, the duration-of-response was lowest in those with the most injections and highest in those with the least injections. The probability of a ≥ 15 ETDRS letter response lasting ≥ 3 months was 58 and 37% in the subgroups receiving one to three and ≥ 7 injections, respectively (Fig. [7](#Fig7){ref-type="fig"}a). Time-to-response and duration-of-response did not vary by sex. More participants with low baseline VA (\< 55 ETDRS letters) responded, and their response was faster and lasted longer than that in the subgroups with higher VA (ESM Figs. S5a, b, S6a, b).Fig. 6Time-to-response (VA improvement of ≥ 15 ETDRS letters from baseline) in treatment-naïve (**a**) and pre-treated participants (**b**). Time-to-response was defined as the first time an improvement of ≥ 15 letters from baseline was reached. Participants who did not reach a response were censored at the last documented time point. If no visual acuity data were documented after baseline, the participant was censored on day 1. Estimators are based on the Kaplan--Meier product-limit methodology. See Fig. [5](#Fig5){ref-type="fig"} caption for abbreviations Fig. 7Duration-of-response (time from first improvement of ≥ 15 ETDRS letters to first time point of losing this improvement) in treatment-naïve (**a**) and pre-treated participants (**b**). Duration-of-response was defined as the time from first improvement of ≥ 15 letters from baseline to the first time point of losing this improvement. Participants who did not lose the response were censored at the last documented time point where the response was still present. If no visual acuity data were documented after the response date, the participant was censored on day 1. Estimators are based on the Kaplan--Meier product-limit methodology. See Fig. [5](#Fig5){ref-type="fig"} caption for abbreviations

The results were similar for the pre-treated population (Figs. [6](#Fig6){ref-type="fig"}b, [7](#Fig7){ref-type="fig"}b; ESM Figs. S4c, d, S5c, d) but less reliable due to the small group size.

Safety {#Sec12}
------

One or more AEs (non-serious and/or serious) were reported for 256 of the 1250 participants in the safety population (20.5%). The most common ocular AEs were increased intraocular pressure (2.6%), reduced VA (2.4%), vitreous hemorrhage, cataract operation (1.4% each) and posterior capsule opacification (1.0%) (ESM Table S3). Serious AEs (SAEs) were reported in 143 participants (11.4%). The most frequent ocular SAEs were vitreous hemorrhage and reduced VA (1.0% each). One SAE of endophthalmitis was reported (0.1%). The main non-ocular SAEs were death (1.0%) and cerebrovascular accident (0.7%).

Discussion {#Sec13}
==========

The real-world treatment of visual impairment due to DME with intravitreal ranibizumab suggests insufficient monitoring and potential under-treatment in Germany. Similar problems have been described in neovascular age-related macular degeneration (nAMD) \[[@CR19], [@CR20]\], but only retrospective data are available on DME \[[@CR13], [@CR14], [@CR21]--[@CR24]\]. Even though the mean number of injections and OCT examinations in our study did not meet current German recommendations, VA gains of ≥ 15 ETDRS letters were reported for over 20% of the participants. Improvements occurred largely within 3 months and were sustained up to month 24. The participants receiving the most (≥ 7) injections in the first year responded the fastest, but their response was less sustained than that of participants receiving fewer injections.

With a mean of 4.42 and 5.52 ranibizumab injections administered over 12 and 24 months, respectively, OCEAN participants with DME received notably fewer than the 7--12 and three to six injections administered in the first and second year, respectively, in previous clinical trials \[[@CR2], [@CR3], [@CR9], [@CR10]\]. A complete four-injection upload as recommended for DME \[[@CR8]\] was documented only in one-third of the participants. These low re-injection rates observed in the study were obtained under conditions of a phase 4 study; as such, they may indicate an even worse re-treatment rate in the "unobserved" routine real-life setting.

Under-treatment with anti-VEGF injections was also observed in retrospective chart reviews of DME. A median of six injections in year 1 and one to two injections in year 2 were documented for 333 individuals with DME at a single German center \[[@CR14]\]. Similarly, a recently published German chart review study with 235 patients documented an average of 5.7 injections in the first year of DME treatment \[[@CR24]\]. This is below the recommendations but still slightly higher than the number of injections in OCEAN, potentially due to a selection bias, as only individuals with ≥ 1 year of follow-up and still actively followed in the clinic were included. OCEAN participants with DME were recruited from 250 centers, including 49 general ophthalmology practices, where monitoring and treatment were documented, but patients were referred to a retina specialist for the injections. Such referrals have been shown to delay treatment start \[[@CR16]\] and may also affect further treatment \[[@CR25], [@CR26]\].

Based on retrospective data from the U.S. IRIS^®^ Registry, a comprehensive eye disease and condition registry, only 47% of people with DME were treated within 1 year of diagnosis. Those given anti-VEGF in the first year received on average 4.2 injections, similar to the number of injections received by participants in OCEAN \[[@CR27]\]. In another USA-based retrospective multicenter study, 156 individuals with DME received on average 5.8 injections in year 1 and 5.0 injections in year 2 \[[@CR13]\], while a third retrospective real-world study in the USA found that patients only received 3.1 injections in the first year of DME treatment \[[@CR28]\]. A Danish retrospective cohort study including 566 patients found that on average 6.1 intravitreal anti-VEGF injections were received in year 1 and 3.0 in year 2 \[[@CR29]\]. Discrepancies between these studies and OCEAN in terms of the number of injections may be due to selection bias or different clinical practice and reimbursement in the USA.

The low number of ranibizumab injections in OCEAN may be due to insufficient OCT monitoring, which is not routinely provided in Germany \[[@CR20]\]. On average, only 3.7 and 5.9 OCT examinations were reported over 12 and 24 months. Very similar figures for Germany were described in another European study (POLARIS), which supports the meaningfulness of the OCEAN data \[[@CR30]\]: the rare use of OCT was also evident in the POLARIS study from the high number of VA examinations. One possible reason for the lower use of OCT may be that OCT examinations in Germany are not reimbursed by the national health insurance and is therefore only included in individual selective contracts or offered as a self-payer service. Some of the OCEAN centers did not even have an OCT device at the start of the study despite the importance of the morphological re-treatment criteria. Many German ophthalmologists refrained from OCT controls during the follow-up. Another finding reported by the authors of the POLARIS study enables comparison between European countries: in Germany treatment often stops or is delayed after the first three injections; in comparison, the higher rate of OCT examinations in the UK was also associated with a considerably higher number of ranibizumab injections \[[@CR30]\].

Non-adherence to monitoring and treatment is a known problem in DME \[[@CR28]\]. In a German real-world study that included 136 individuals with DME receiving anti-VEGF only 35% adhered to the visit schedule \[[@CR12]\]. Another real-world study in Germany that included 134 individuals with DME receiving anti-VEGF found a non-adherence rate of 44%, which was mostly patient associated \[[@CR23]\]. Possible reasons for non-adherence include comorbidities, patient age \[[@CR12], [@CR23]\] and/or the high visit burden, particularly since individuals with DME also require frequent diabetes monitoring. It has also been suggested that adherence may be hampered by reimbursement issues, mobility limitations, a lack of patient motivation and interference with work schedules \[[@CR28]\]. Even with appropriate monitoring, some physicians may use re-injection criteria that differ from the recommendations. It is also possible that recommendations were followed but that participants were not treated because they met success or stop criteria or refused treatment; while this last possibility cannot be discerned from the data, but it is unlikely.

Despite under-treatment, VA notably improved in OCEAN participants with DME after 12 months (+ 4.0  ETDRS letters) and 24 months (+ 5.2 letters). Participants with low baseline VA (\< 55 letters) and those receiving ≥ 7 injections in year 1 showed the highest gains. The VA improved less than in patients with DME in randomized controlled trials such as. RESTORE \[[@CR7]\], Protocol I \[[@CR31]\] and Protocol T \[[@CR2]\] where participants given ranibizumab with or without laser photocoagulation gained between + 7 and + 12 ETDRS letters. Clinical trials have strict treatment and follow-up schedules and inclusion/exclusion criteria, which may lead to better outcomes.

The VA improvements in patients in the prospective OCEAN study were also slightly lower than improvements reported in retrospective chart reviews. Two UK-based studies showed improvements of + 5 ETDRS letters \[[@CR22]\] and + 6.6 letters \[[@CR21]\] at 12 months. The latter study selected individuals receiving a ≥ 3-injection upload who may be expected to have better results. In a German retrospective study \[[@CR14]\], the maximum improvement for DME within 12 months was + 6.2 ETDRS letters, but the change from baseline to month 12 was − 1.3 letters. This VA loss may be due to bias, as only patients still under treatment were included, preferentially selecting individuals with chronically active disease \[[@CR14]\]. A second German chart review study documented VA gains of + 5.6 ETDRS letters in the first year of ranibizumab treatment \[[@CR24]\]. A small retrospective study from Taiwan found average improvement of + 4.9 ETDRS letters at 12 months with a mean injection load of 4.3 injections \[[@CR32]\].

About 60% of the participants completed the OCEAN study, which is comparable with other non-interventional studies, such as the AURA study on ranibizumab treatment for nAMD, where 53% completed 2 years \[[@CR33]\]. Time-to-event analyses have the advantage of including participants irrespective of the length of their individual observational period and missing data. The discontinuation rate among the participants in the OCEAN study was quite constant, suggesting that no specific factor triggered discontinuation at a particular time point. Participants receiving one to three injections during year 1 were documented for a shorter period than participants with more injections. It cannot be determined whether participants leaving the study early continued treatment outside the study.

Over 20% of the OCEAN participants with DME showed a relevant VA improvement (≥ 15 ETDRS letters) at months 12 and 24. Most participants responded within 3 months, consistent with the fast responses shown in clinical trials \[[@CR2], [@CR7]\]. The response rate was higher in individuals receiving ≥ 7 injections in year 1, suggesting that more injections, potentially due to better adherence, increase VA gains. However, as a considerable proportion of participants discontinued the study early, and the group with ≥ 7 injections was small, this finding may not be transferrable to the general DME population.

By contrast, the duration-of-response was shortest in participants receiving the most injections. This could mean that participants receiving more injections do so because they respond to treatment but require additional ranibizumab injections to maintain the beneficial effects, such as due to higher disease activity.

Participants with the lowest baseline VA (\< 55 ETDRS letters) showed the highest VA gain ('floor effect'), and the response was faster and lasted longer than that in the subgroups with higher VA, demonstrating that individuals with DME and significantly impaired VA achieve sustainable improvements with ranibizumab. Participants with baseline VA of \> 68 ETDRS letters gained less ('ceiling effect') but maintained higher VA than that of the other subgroups, supporting the need for prompt monitoring and treatment to prevent vision loss from DME \[[@CR34]\].

No new safety findings were identified in this population. The documented incidence of AEs (20.5%) and SAEs (11.4%) over 2 years was lower than those reported in randomized trials \[[@CR2], [@CR31]\], potentially due to under-reporting in this non-interventional setting.

The non-interventional design is a strength of this study, as it describes the use of ranibizumab therapy for DME in routine clinical practice, in patients who are older and have more comorbidities than those in clinical trials \[[@CR11], [@CR15]\] and who may also have more difficulties adhering to the treatment schedule. Seeing a beneficial effect of ranibizumab with a well-characterized safety profile in this setting is encouraging.

Non-interventional studies harbor a number of important limitations, including non-standardized diagnostics, high discontinuation rates, under-reporting, artificial patient selection and selective reporting; all of these have to be kept in mind when interpreting the results. Although even randomized controlled trials reported a loss of follow-up of between 23.4% (NCT00473382) and 42.1% (NCT00168389) of DME patients over 3 years, the group of discontinued documentation and treatment in the daily routine is more strongly associated with a distortion potential and thus does likely not reflect the actual distribution of the functional response. In this study, we have tried to describe this window of uncertainty and take account the limited tracking through a transparent and robust methodology.

Conclusion {#Sec14}
==========

In conclusion, the large non-interventional OCEAN study demonstrated that despite insufficient monitoring and potential under-treatment, substantial improvements of VA could be achieved with ranibizumab (0.5 mg) in \> 20% of adults with DME. As the response rate was higher in participants receiving more injections, improving access and adherence to treatment may increase the benefits of this cost- and resource-intensive therapy.
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